Evaluation of Protocol Biopsy Utility 12 Months after Renal Transplantation: A Multicenter Observational Analysis

Table 2

Modification of immunosuppression following biopsy and local diagnosis of normal, IF/TA or immunosuppression-related toxicity. All differences were nonsignificant.

	Surveillance biopsy (𝑛=154)	Diagnostic biopsy (𝑛=11)
All biopsies, 𝑛 (%)
No change	106 (68.8)	7 (63.6)
Continue CNI & MPA, both at reduced doses	32 (20.8)	3 (27.3)
Continue CNI & MPA with reduced CNI dose	2 (1.3)	1 (9.1)
Switch from CNI to another therapeutic class	3 (1.9)	0
Switch from MPA to another therapeutic class	2 (1.3)	0
Other	9 (5.8)	0
Normal, 𝑛 (%)	𝑁=65	𝑁=1
No change	55 (84.6)	1 (100.0)
Continue CNI & MPA, both at reduced doses	10 (15.4)	0
IF/TA, 𝑛 (%)	𝑁=33	𝑁=1
No change	18 (54.5)	0
Continue CNI & MPA, both at reduced doses	9 (27.3)	1 (100.0)
Switch from CNI to another therapeutic class	2 (6.1)	0
Switch from MPA to another therapeutic class	1 (3.0)	0
Other	3 (9.1)	0
CNI-related toxicity, 𝑛 (%)	𝑁=19	𝑁=5
No change	5 (26.3)	3 (60.0)
Continue CNI & MPA, both at reduced doses	11 (57.9)	2 (40.0)
Continue CNI & MPA with reduced CNI dose	2 (10.5)	0
Switch from CNI to another therapeutic class	1 (5.3)	0

IF/TA: interstitial fibrosis/tubular atrophy; CNI: calcineurin inhibitor; MPA: mycophenolic acid.